A novel phosphatase cascade regulates differentiation in *Trypanosoma brucei* via a glycosomal signaling pathway

Balázs Szöör,^{1,4} Irene Ruberto,¹ Richard Burchmore,² and Keith R. Matthews^{1,3}

¹Centre for Immunity, Infection, and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3JT, United Kingdom; ²Sir Henry Wellcome Proteomics Facility, University of Glasgow G12 8QQ, United Kingdom

In the mammalian bloodstream, the sleeping sickness parasite *Trypanosoma brucei* is held poised for transmission by the activity of a tyrosine phosphatase, *TbPTP1*. This prevents differentiation of the transmissible “stumpy forms” until entry into the tsetse fly, whereupon *TbPTP1* is inactivated and major changes in parasite physiology are initiated to allow colonization of the arthropod vector. Using a substrate-trapping approach, we identified the downstream step in this developmental signaling pathway as a DxTxT phosphatase, *TbPIP39*, which is activated upon tyrosine phosphorylation, and hence is negatively regulated by *TbPTP1*. In vitro, *TbPIP39* promotes the activity of *TbPTP1*, thereby reinforcing its own repression, this being alleviated by the trypanosome differentiation triggers citrate and *cis*-aconitate, generating a potentially bistable regulatory switch. Supporting a role in signal transduction, *TbPIP39* becomes rapidly tyrosine-phosphorylated during differentiation, and RNAi-mediated transcript ablation in stumpy forms inhibits parasite development. Interestingly, *TbPIP39* localizes in glycosomes, peroxisome-like organelles that compartmentalize the trypanosome glycolytic reactions among other enzymatic activities. Our results invoke a phosphatase signaling cascade in which the developmental signal is trafficked to a unique metabolic organelle in the parasite: the glycosome. This is the first characterized environmental signaling pathway targeted directly to a peroxisome-like organelle in any eukaryotic cell.

[**Keywords:** Glycosome; peroxisome; signal transduction; phosphatase; *Trypanosoma brucei*; differentiation]

Supplemental material is available at <http://www.genesdev.org>.

Received November 26, 2009; revised version accepted April 22, 2010.

Developmental events in eukaryotic cells are often driven by a transmembrane signaling event, this being transduced via phosphorylation/dephosphorylation of signaling proteins to generate a cellular response. Such signaling events are particularly important in unicellular eukaryotes, which are required to react to external stimuli, either as part of an adaptive response to a changing environment, or through triggered developmental responses intrinsic to their normal life cycle progression. An excellent model for such developmentally regulated responses is the African trypanosome, *Trypanosoma brucei* (Fenn and Matthews 2007). These are important disease organisms of sub-Saharan Africa, where they generate significant problems for public health and economic welfare (Barrett et al. 2003). Furthermore, as highly diverged and evolutionarily ancient organisms (Sogin et al. 1986), they have provided

an important paradigm for organelle evolution and function in the eukaryotic cell (Hannaert et al. 2003; He et al. 2004, 2005; Broadhead et al. 2006; He 2007), exemplified by their use of extensive RNA editing for mitochondrial transcripts (Stuart et al. 2005), and by their possession of unusual peroxisome-like organelles, glycosomes (Oppendoes 1987). These compartmentalize the trypanosome glycolytic enzymes, which in other eukaryotes are cytosolic, thereby avoiding the lethal consequences of the “turbo design” of glycolysis (Teusink et al. 1998; Bakker et al. 2000). Glycosomes also contain enzymes required for ether lipid biosynthesis, the β oxidation of fatty acids, as well as several additional activities (Michels et al. 2006; Oppendoes and Szikora 2006), although their precise enzymatic composition and number is regulated during the trypanosome life cycle (Michels et al. 2006).

The life cycle regulation of organellar function is a central component of the developmental biology of the trypanosome, which entails extensive cellular remodeling during passage from the mammalian blood to the mid-gut of the tsetse fly, the parasite’s vector (Matthews 2005). These differentiation events are triggered by exposure

Corresponding authors.

³E-MAIL keith.matthews@ed.ac.uk; FAX 44-131-651-3670.

⁴E-MAIL Balazs.Szoor@ed.ac.uk; FAX 44-131-651-3670.

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.570310>.

Freely available online through the *Genes & Development* Open Access option.

of bloodstream parasites to citrate/*cis*-aconitate (CCA) (Czichos et al. 1986; Engstler and Boshart 2004). This signal is transduced via a family of surface transporters, PAD proteins (Dean et al. 2009), with signal recognition being promoted by temperature reduction to 20°C—conditions encountered upon uptake by feeding tsetse flies (Engstler and Boshart 2004). PAD proteins are expressed on the cell surface of stumpy forms, the stage of the bloodstream parasite population adapted for transmission to tsetse flies. Importantly, stumpy forms are held ready for this developmental change by the action of a tyrosine phosphatase, *TbPtp1* (Szöör et al. 2006), until differentiation is triggered. Thus, the activity of *TbPtp1* prevents stumpy forms from initiating differentiation and, when this enzyme is inactivated after exposure to either CCA or chemical inhibitors of PTPs, the cells differentiate from bloodstream to procyclic forms (Szöör et al. 2006). This places *TbPtp1* at the head of an intracellular signaling pathway whose components are completely unknown.

Here we exploited a tyrosine phosphatase substrate selection strategy to identify the downstream step in the differentiation signaling pathway. This has identified a glycosomally targeted DxDxT family Ser/Thr phosphatase, invoking the presence of a phosphatase signaling cascade directing developmental regulation in trypanosomes. Our findings provide the first evidence of developmentally regulated signal transduction via the glycosome, and link the external differentiation stimulus through this signaling pathway to control of the trypanosome life cycle.

Results

TbPtp1 substrate is a novel DxDxT phosphatase, *TbPIP39*

To identify potential substrates of *TbPtp1*, we exploited the ability to generate mutant PTP enzymes, which bind but do not release substrates (Blanchetot et al. 2005). Specifically, His-tagged *TbPtp1* was generated in which residue 199, the catalytic aspartic acid in the predicted WPD loop (Szöör et al. 2006), was mutated to alanine. This “substrate-trapping” mutant (*TbPtp1*-D199A) was bound to a His trap chelating column, and was used to select interacting proteins and substrates of *TbPtp1* from stumpy cell lysates. Mass spectrometry reproducibly identified a selected protein encoded by a gene on chromosome 9, *Tb09.160.4460*, this being almost identical (339 out of 343 amino acids) to that encoded by its immediately downstream gene (*Tb09.160.4480*), invoking a gene duplication event. *Tb09.160.4460* encodes a protein with a predicted molecular mass of 39 kDa, this being named *TbPIP39* (*TbPtp1*-interacting protein, 39 kDa). The *TbPIP39* gene is well conserved in those kinetoplastids that have been subject to genome sequence analysis, although in *Trypanosoma cruzi*, *Trypanosoma vivax*, and *Leishmania major*, it has not undergone gene duplication (Supplemental Fig. 1).

To confirm the interaction between *TbPtp1* and *TbPIP39*, an antibody was raised to *TbPIP39* and used to

probe the eluate from stumpy cell lysates incubated with either His-tagged *TbPtp1*-D199A or wild-type *TbPtp1*. Figure 1A demonstrates that the binding of *TbPIP39* to the substrate-trapping *TbPtp1*-D199A was much more effective than to the wild-type protein (Fig. 1A, lanes 2,3). To validate this interaction *in vivo*, transgenic bloodstream forms were generated ectopically expressing wild-type *TbPtp1* or *TbPtp1*-D199A proteins, each with a C-terminal Ty1 epitope tag (Bastin et al. 1996). Since *TbPIP39* expression is induced during differentiation (see later), cells were treated with *cis*-aconitate for 24 h, and Ty1-specific antibody was used to immunoprecipitate *TbPtp1*. This revealed coimmunoprecipitation of *TbPIP39* with the *TbPtp1*-D199A substrate-trapping mutant, selection being blocked in the presence of a synthetic peptide comprising the Ty1 epitope (Fig. 1B, cf. lanes 3 and 5). Matching the *in vitro* pull-down assay, *TbPIP39* was selected less efficiently with wild-type *TbPtp1* (Fig. 1B, cf. lanes 5 and 10), supportive of the interaction being stabilized by the substrate-trapping mutation. Confirming

Figure 1. *TbPtp1* interacts with *TbPIP39* *in vitro* and *in vivo*. (A) Substrate-trapping selection of *TbPIP39* by *TbPtp1*. Wild-type (WT) or substrate-trapping recombinant *TbPtp1* (D199A) was expressed as a His-tagged fusion protein and then bound to a His trap chelating column. Lysate from 5×10^8 stumpy cells was then passed over the column in order to select interacting proteins. Bound material was eluted from the beads and reacted with either antibody specific for the His tag (detecting the *TbPtp1* ligand), or *TbPIP39*. *TbPIP39* was preferentially selected by the D199A *TbPtp1* substrate-trapping mutant. (B) Wild-type or D199A *TbPtp1*-Ty was expressed in cultured bloodstream form *T. brucei*, which were then induced to differentiate to procyclic forms for 24 h by the addition of 6 mM *cis*-aconitate. Immunoprecipitation was then performed using the TY-1 epitope-specific antibody, which had been incubated either with (“blocked beads”) or without a peptide sequence recognized by the antibody. Input cell lysate, flow-through (ft), or precipitated material (beads) from each immunoprecipitation, either with or without blocking, was then reacted with the Ty1-specific antibody (to detect the ectopically expressed *TbPtp1* or D199A *TbPtp1*) or antibodies detecting *TbPIP39* or aldolase (as a negative control). The D199A-trapping mutant of *TbPtp1* preferentially selected *TbPIP39*, whereas aldolase was not selected.

specificity, an unrelated protein, aldolase, was not coselected by immunoprecipitation of the substrate-trapping or wild-type *TbPPT1* (Fig. 1B).

Examination of the sequence of *TbPIP39* and its orthologous sequences in related kinetoplastids revealed the presence of a conserved predicted tyrosine phosphorylation site (Y278) toward the C terminus (Supplemental Fig. 1A). Although the trypanosome genome encodes no tyrosine-specific kinases (Parsons et al. 2005), a group-based phosphorylation scoring analysis (Xue et al. 2005) predicted that the Y278 residue could be phosphorylated effectively in vitro by the human Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog FGR kinase. Confirming this, incubating recombinant *TbPIP39* with FGR kinase rapidly generated tyrosine-phosphorylated *TbPIP39* (Fig. 2A, left panel), whereas mutation of Y278 to phenylalanine (Y278F) in *TbPIP39* prevented tyrosine phosphorylation under the same conditions (Fig. 2A, right panel). Tyrosine-phosphorylated *TbPIP39* was then incubated with either wild-type *TbPPT1*, or a catalytically dead mutant of *TbPPT1* in which the active site cysteine was mutated to serine (C229S). Figure 2B demonstrates that *TbPIP39* was effectively dephosphorylated by wild-type *TbPPT1*, but not by the inactive C229S mutant, establishing that *TbPIP39* not only interacted with substrate-trapping *TbPPT1* in cell lysates, but that it could form a *TbPPT1* substrate.

Regulatory interactions between *TbPPT1* and *TbPIP39*

The protein sequence of *TbPIP39* suggested that it was a member of an unusual class of serine/threonine phosphatases, with a characteristic DxDx (T/V) motif toward the N terminus of the predicted catalytic domain (Supplemental Fig. 1A). This family of proteins comprises FCP1/SCP1, responsible for the dephosphorylation of the eukaryotic C-terminal domain of RNA polymerase II (Kamenski et al. 2004), as well as several stress response phosphatases, typified by the yeast haloacid dehalogenase-type phosphatases PSR1/PSR2 (Siniosoglou et al. 2000) and a phosphatase required in nuclear membrane biogenesis, Dullard (Kim et al. 2007). The catalytic activity of this group of phosphatases depends on magnesium ions, requiring the integrity of the DxDxT motif as the intermediate phosphoryl acceptor (Collet et al. 1998). Consistent with this, the activity of recombinant *TbPIP39* against the artificial phosphatase substrate pNPP was enhanced dramatically ($P < 0.001$) in the presence of 15 mM Mg^{2+} (Fig. 2C, columns 1,2). Moreover, when residues 55D and 57D were each mutated to glutamic acid (*TbPIP39dEdE*), no catalytic activity could be detected under the same conditions (Fig. 2C, column 3).

To investigate the possibility that the tyrosine phosphorylation status of *TbPIP39* might modulate its activity, the activity of *TbPIP39* against pNPP was assayed at time points after incubation with FGR kinase to generate the tyrosine-phosphorylated form (Fig. 2D). As a control, the nonphosphorylatable *TbPIP39* mutant (Y278F) was incubated under the same conditions. *TbPIP39* activity was progressively enhanced with increasing phosphory-

Figure 2. *TbPIP39* is a phosphatase with regulatory interaction with *TbPPT1*. (A). Recombinant *TbPIP39* was incubated with FGR kinase to generate a tyrosine-phosphorylated form over the course of 120 min. Tyrosine phosphorylation of the recombinant protein was detected using the phosphotyrosine-specific antibody 4G10 (α -pTyr; Millipore). The right panel shows the same analysis using a mutant form of *TbPIP39* in which the predicted tyrosine phosphorylation site Y278 is mutated to phenylalanine (F278). In this case, α -pTyr reactivity is lost. (B) Tyrosine-phosphorylated *TbPIP39* is a substrate of *TbPPT1*. *TbPIP39* was incubated with FGR kinase to generate tyrosine-phosphorylated protein, this being detected with the 4G10 antibody (α -pTyr). Upon incubation with wild-type *TbPPT1*, tyrosine phosphorylation of *TbPIP39* is lost. In contrast, when incubated with either buffer alone or a catalytically dead (C229S) *TbPPT1* mutant, *TbPIP39* remains phosphorylated. (C) Activity against pNPP of recombinant *TbPIP39* in the absence (column 1) or presence (column 2) of Mg^{2+} . Column 3 shows the same assay as in column 2, using a dEdE mutant of *TbPIP39*. Columns 4–7 show the activity against pNPP of *TbPPT1* alone (column 4) or in the presence of 1 μ g (column 5), 0.1 μ g (column 6), or 0.01 μ g of *TbPIP39*. No Mg^{2+} was included in the reactions in columns 4–7, preventing *TbPIP39* activity. Statistical analyses used a general linear model. (*) $P < 0.05$; (**) $P < 0.001$. (D) Activity against pNPP of recombinant *TbPIP39* as it becomes tyrosine-phosphorylated by FGR kinase. With increasing phosphorylation, the activity increases. (Right graphs) In *TbPIP39*-Y278F, no enhanced activity is observed, demonstrating that tyrosine phosphorylation on Y278 is responsible for *TbPIP39* regulation. The input recombinant proteins are those depicted in A. Statistical analyses used a general linear model. (*) $P < 0.05$.

lation, while the nonphosphorylatable mutant showed no enhanced activity above its baseline activity. This confirmed that the activity of *TbPIP39* was enhanced upon

the phosphorylation of Y278, this site being the target of *Tb*PTP1 activity (Fig. 2B).

As well as *Tb*PTP1 regulating *Tb*PIP39 activity, we also found evidence that *Tb*PIP39 could reciprocally influence the activity of *Tb*PTP1. Thus, although 1 μ g of *Tb*PIP39 showed negligible activity against pNPP in the absence of magnesium (Fig. 2C, column 1), when it was incubated together with 0.1 μ g of *Tb*PTP1, the overall activity of the combined phosphatase enzymes was significantly greater than the activity of 0.1 μ g of *Tb*PTP1 alone (Fig. 2C, cf. columns 1,4,5). Confirming that this was due to the activity of *Tb*PTP1, the same analysis using the inactive D199A mutant of *Tb*PTP1 generated no increase in phosphatase activity (Supplemental Fig. 2). This demonstrated that a positive interaction existed between *Tb*PTP1 and *Tb*PIP39, such that *Tb*PIP39 promoted the activity of *Tb*PTP1 when in significant molar excess.

In a final assay of the interaction between *Tb*PIP39 and *Tb*PTP1, we investigated the effect on their respective phosphatase activities of incubation with citrate, which acts as a trypanosome differentiation trigger. This was prompted by the structural analysis of the DxDxT class phosphatase SCP1, which exhibits a citrate-binding pocket (Kamenski et al. 2004), the required residues for which are conserved in *Tb*PIP39 (Supplemental Fig. 1A). Therefore, we investigated the ability of citrate and the structurally related differentiation trigger *cis*-aconitate to moderate the activity of either *Tb*PIP39 or *Tb*PTP1, or the two phosphatases in combination (Supplemental Fig. 3A,B, columns 5–8). This demonstrated that both metabolites produced a concentration-dependent reduction of the enhanced phosphatase activity of *Tb*PTP1/*Tb*PIP39 when combined. Eliminating the possibility that divalent cat-

ion chelation was responsible for this, citrate or *cis*-aconitate had no effect on either *Tb*PIP39 or *Tb*PTP1 alone (Supplemental Fig. 3A,B, columns 1–4,9–12).

Combined, these experiments demonstrated that *Tb*PIP39 showed less activity when nonphosphorylated, i.e., as the product of *Tb*PTP1 activity, whereas *Tb*PIP39 could activate *Tb*PTP1. Moreover, we found that this regulatory interaction between *Tb*PTP1 and *Tb*PIP39 was abolished by citrate and *cis*-aconitate, both of which act as trypanosome differentiation stimuli.

Life cycle regulation and glycosomal location of *Tb*PIP39

*Tb*PTP1 acts in stumpy forms to prevent the parasites undergoing spontaneous differentiation to procyclic forms (Szöör et al. 2006). To investigate whether its substrate, *Tb*PIP39, was present at the same life cycle stage, the RNA and protein expression of *Tb*PIP39 was investigated in bloodstream slender, bloodstream stumpy, and cultured procyclic forms of *T. brucei*. Although the mRNA for *Tb*PIP39 was abundant in all life cycle stages (albeit enriched in bloodstream stumpy forms) (Fig. 3A), *Tb*PIP39 protein was barely detectable in slender forms, but was expressed in stumpy and elevated during differentiation and in procyclic forms (Fig. 3B; Supplemental Fig. 4A), demonstrating regulation at the level of protein synthesis or turnover. Interestingly, the migration of the *Tb*PIP39 protein was altered between stumpy and procyclic forms (Fig. 3B), there being a slightly higher-molecular-weight form in the latter. This was expected to represent the phosphorylated form of *Tb*PIP39. To establish the tyrosine phosphorylation status of *Tb*PIP39 during differentiation,

Figure 3. *Tb*PIP39 is a procyclic-enriched glycosomal phosphoprotein. (A) Northern blot of *Tb*PIP39 expression in bloodstream slender (SI), bloodstream stumpy (St), or cultured procyclic (Pro) forms. The bottom panel shows the ethidium bromide-stained rRNA, indicating loading. (B) Western blot of *Tb*PIP39 in bloodstream slender (SI), bloodstream stumpy (St), or cultured procyclic (Pro) forms. In stumpy forms, a lower-molecular-weight form is observed, whereas in procyclic forms, a higher-molecular-weight form predominates (arrowheads). The constitutively expressed protein *Tb*ZFP3 (Paterou et al. 2006) is included as a loading control. An empty intervening lane between the stumpy and procyclic form samples has been removed for clarity. (C) Digitonin fractionation of procyclic and stumpy

form cells reacted with an antibody specific for *Tb*PIP39, *Tb*PIP39 (phospho-Y278), a glycosomal protein (aldolase), or a cytosolic protein (cytosolic PGK). Exposures have been adjusted to best reveal the distribution between fractions for each protein and are not equivalent between the distinct profiles. In each case, the digitonin concentration is shown with the cell extract being separated into either soluble or pelleted (organellar) fractions. *Tb*PIP39 cofractionates with glycosomal aldolase. A quantitative analysis of the fractionation of procyclic forms is shown in Supplemental Figure 6. (D) Localization of *Tb*PIP39 (red) with an N-terminal GFP fusion of the glycosomal protein *Tb*PEX13 (green). The two proteins colocalize precisely. DNA of the cells was counterstained using DAPI (blue). Bar, 5 μ m.

an anti-peptide tyrosine phospho-specific antibody directed to Y278 of *TbPIP39* (ELD HWR TDE Y*TK C) was generated. This revealed enhanced phosphorylation of *TbPIP39* within 120 min of exposure to *cis*-aconitate or the tyrosine phosphatase inhibitor BZ3 (Supplemental Fig. 4B). Moreover, reactivity of the phospho-specific antibody was lost upon treatment of procyclic cell extracts with *TbPPT1* (Supplemental Fig. 5B C), establishing Y278 as the tyrosine phosphorylation site of *TbPIP39* in vivo and the target of *TbPPT1*. The expression of *TbPIP39* was also elevated in stumpy forms exposed to 20°C (Supplemental Fig. 4C)—conditions that sensitize trypanosomes to the differentiation stimuli CCA (Engstler and Boshart 2004), and elevate the expression and surface distribution of PAD2, one member of the protein family responsible for conveying the CCA differentiation signal (Dean et al. 2009). Hence, the developmental expression, thermal regulation, and predicted phosphorylation profile of *TbPIP39* matched expectations for a *TbPPT1* substrate involved in the differentiation control pathway.

When the cellular location of *TbPIP39* was investigated by immunofluorescence, a punctate staining was detected, similar to that of trypanosome glycosomal proteins. This was supported by the analysis of the *TbPIP39* protein sequence, which exhibited a predicted C-terminal peroxisomal location signal (PTS1) (–SRL) (Supplemental Fig. 1A; Oppendoes and Szikora 2006), and the detection of *TbPIP39* in purified procyclic form glycosomes by proteomic analysis (Colasante et al. 2006). Nonetheless, to verify that *TbPIP39* associated with the glycosomes, we assessed the fractionation of the protein under a digitonin detergent titration. This demonstrated that *TbPIP39* cofractionated with a glycosomal marker protein (aldolase) in both procyclic and stumpy forms, this profile being shared with the phosphorylated form of *TbPIP39* detected using the Y278 phospho-specific antibody (Fig. 3C; Supplemental Fig. 6B). Confirming its association with glycosomes, *TbPIP39* colocalized with GFP in a transgenic procyclic line expressing an N-terminal GFP fusion of *TbPEX13*, a glycosomal import protein (Fig. 3D; Verplaetse et al. 2009; the plasmid was a kind gift of P. Michels, Brussels). Hence, by sequence prediction, biochemical and cellular fractionation, and colocalization studies, *TbPIP39* was identified as a glycosome-associated protein.

TbPIP39 RNAi inhibits differentiation of bloodstream forms

To investigate whether *TbPIP39* was a component of the differentiation signaling pathway, its mRNA was ablated by tetracycline-regulated RNAi. To assay early differentiation events in a biologically relevant context, it was important to assay stumpy cells capable of synchronous differentiation to procyclic forms. Thus, the *T. brucei* AnTat1.1 90:13 pleomorphic line was transfected with the stem-loop RNAi vector pALC14 containing opposing fragments of the *TbPIP39* gene. A transfectant line was then grown for 6 d in mice provided either without (–DOX) or with (+DOX) 200 µg/mL doxycycline in their drinking water to induce transcript ablation, and hence

prevent *TbPIP39* protein expression in developing stumpy forms. Although *TbPIP39* was ~85% depleted in the +DOX parasites (Fig. 4A), no reproducible difference between the progression of the parasitaemia for the uninduced (–DOX) or induced (+DOX) parasites was observed; moreover, both samples generated highly enriched stumpy form populations within 6 d (Supplemental Fig. 7). This demonstrated that *TbPIP39* was not required for stumpy formation or viability. The stumpy forms were then harvested and incubated for 16 h at either 37°C or 20°C, the latter sensitizing the parasites to physiological levels of CCA (i.e., ~0.1 mM) (Engstler and Boshart 2004; Dean et al. 2009). Both the +DOX and –DOX populations were then exposed to 0 mM, 0.1 mM, or 6 mM *cis*-aconitate in vitro and assayed for their expression of the differentiation marker EP procyclin after 4 and 24 h to detect effects on the initiation of

Figure 4. *TbPIP39* depletion in stumpy forms inhibits differentiation. (A) Western blots of *TbPIP39* from samples derived from *TbPIP39*-RNAi cells either induced (+Dox) or uninduced (–Dox) with doxycycline. Samples were incubated overnight at 20°C, and then proteins were isolated 0 h, 4 h, or 24 h after exposure to 0 mM, 0.1 mM, or 6 mM *cis*-aconitate. The bottom panels represent analysis of the same samples using an antibody against α -tubulin as a loading control. (B) Flow cytometry traces of EP procyclin expression in four independent stumpy cell populations either induced (+Dox, orange and green traces) or not (–Dox, blue and red traces) to ablate *TbPIP39* by RNAi. Individual stumpy cell samples were derived from day 6 infections of mice either with or without doxycycline in their drinking water. Samples were incubated at 20°C before the addition of *cis*-aconitate, and flow cytometry was carried out either 4 h or 24 h later. The induced populations showed reduced differentiation at 0.1 mM (4 h and 24 h); at 6 mM, differentiation was efficient in all populations (likely enabled by the remaining ~15% *TbPIP39* in the RNAi line), although it was delayed in the induced samples. Flow cytometry traces from this experiment with cells incubated at 37°C are available in Supplemental Figure 8.

differentiation. Although the extent of *Tb*PIP39 depletion and the overall kinetics of EP procyclin expression in different experiments varied, perhaps reflecting the amount of remaining enzyme following RNAi (~15%), the *Tb*PIP39-depleted parasites showed reduced differentiation with 0.1 mM *cis*-aconitate (mean, 58% reduction; range, 52%–67% reduction at 24 h) (Fig. 4B), this effect being consistent in five out of five experiments, whereas at 6 mM *cis*-aconitate, an effect of *Tb*PIP39 depletion was observed in only two out of five experiments. Hence, the depletion of *Tb*PIP39 reduced the differentiation of stumpy forms, with a reduction of sensitivity to physiological levels of CCA. Being detected in uniform populations of cells before the onset of outgrowth as procyclic forms, we conclude that *Tb*PIP39 acts as a positive signaling component operating downstream from, and negatively regulated by, *Tb*PTP1.

To confirm that the differentiation signaling response required the glycosomal location of *Tb*PIP39, we investigated the ability of mutants with a deleted or an epitope tag-blocked C-terminal PTS1 signal to rescue the *Tb*PIP39 RNAi-mediated differentiation phenotype. To achieve this, monomorphic bloodstream forms capable of *Tb*PIP39 RNAi (Supplemental Fig. 9) were engineered to express recoded synthetic genes that would be immune to RNAi, but encode proteins of the same amino sequence as endogenous *Tb*PIP39 (Supplemental Fig. 10A,B). Initially, the monomorphic *Tb*PIP39 RNAi line was stimulated to differentiate with *cis*-aconitate, demonstrating reduced procyclin expression over 48 h when RNAi was induced with tetracycline (Fig. 5A). When a wild-type recoded *Tb*PIP39 copy was coexpressed in the same line, however, differentiation was fully restored, supporting rescue of the phenotype (Fig. 5B). In contrast, the expression of *Tb*PIP39 Δ SRL or *Tb*PIP39-C terminal Ty, both of which were cytosolic by digitonin fractionation (Supplemental Fig. 10C), failed to rescue the differentiation phenotype (Fig. 5C,D), as did a catalytically inactive (*Tb*PIP39dEdE) *Tb*PIP39 mutant (Fig. 5E). These observations support the glycosomal location and activity of *Tb*PIP39 being important for differentiation signaling.

Discussion

We demonstrated previously that the tyrosine phosphatase *Tb*PTP1 acts as a “molecular brake” that prevents differentiation of bloodstreams stumpy forms in the mammalian bloodstream (Szöör et al. 2006). In this study, we identify a downstream substrate of *Tb*PTP1 as a second phosphatase, *Tb*PIP39. *Tb*PIP39 is shown to be a developmentally regulated magnesium-dependent phosphatase whose activity is modulated by tyrosine phosphorylation. Moreover, we show that *Tb*PIP39 contributes to the efficient differentiation to procyclic forms, thereby invoking the existence of a phosphatase signaling cascade regulating trypanosome development. Supporting this, we show regulatory cross-talk between *Tb*PIP39 and *Tb*PTP1 in vitro, this being abolished by the differentiation regulators citrate and *cis*-aconitate. Finally, we demonstrate that *Tb*PIP39 is glycosomal, identifying this

Figure 5. An intact glycosomal targeting signal is required for *Tb*PIP39-dependent differentiation. (A) *T. brucei* single-marker bloodstream forms were transfected with the *Tb*PIP39 RNAi construct used in Figure 4. The resulting transfectant cell line was then induced (blue) or not induced (red) to ablate *Tb*PIP39 by incubation with 1 μ g/mL tetracycline for 2 d. The RNAi-depleted cells and the uninduced controls were then stimulated to differentiate to procyclic forms by the addition of 6 mM *cis*-aconitate and the expression of the differentiation marker EP procyclin monitored by flow cytometry. Depletion of *Tb*PIP39 resulted in reduced differentiation efficiency at 48 h after exposure to *cis*-aconitate. (B) The same cell line as in A was transfected with pHD451 expressing an intact recoded synthetic *Tb*PIP39 gene, expressed under tetracycline regulation. Cells were grown with tetracycline for 2 d, allowing silencing of the endogenous *Tb*PIP39 transcript and expression of the recoded gene. Differentiation was then monitored for EP procyclin expression 48 h after exposure to 6 mM *cis*-aconitate using flow cytometry. The differentiation phenotype was fully rescued. (C) As in B, but the recoded synthetic gene product lacked the Δ SRL glycosomal targeting signal and redistributed to the cytosolic fraction (Supplemental Fig. 10C). In this case, the differentiation defect was not rescued. (D) As in B, but the recoded synthetic gene product contained a Ty1 epitope tag after the Δ SRL glycosomal targeting signal. As with the truncated mutant, the protein was redistributed to the cytosolic fraction (Supplemental Fig. 10C) and the differentiation defect was not rescued. (E) As in B, but the recoded synthetic gene product was mutated for the DxTxT motif (to ExExT) to prevent catalytic activity. No rescue of the differentiation defect was observed.

molecule as a new marker for distinguishing bloodstream from procyclic form glycosomes, and the first example of a signaling molecule targeted to this fundamental metabolic organelle in trypanosomes. To our knowledge, this is the first well-characterized signaling pathway targeted directly to a peroxisomal-type organelle in any eukaryotic cell.

*Tb*PIP39 was identified as an unusual type of Ser/Thr phosphatase, a DxTxT phosphatase. This is an emerging family of phosphatases, and one of a group of such phosphatases encoded in kinetoplastid genomes (14, 13, and 13 members, in *T. brucei*, *T. cruzi*, and *L. major*, respectively)

(Brenchley et al. 2007), but the only representative possessing a predicted PTS1. Consistent with expectations for this class of molecules (Selengut and Levine 2000; Ndubuisi et al. 2002), *Tb*PIP39 showed magnesium-dependent activity, with its activity being abolished by mutation of the predicted magnesium-coordinating aspartate residues in the DxTxT phosphoryl acceptor motif (Collet et al. 1998). Interestingly, however, when *Tb*PIP39 was coincubated with *Tb*PPT1, the overall phosphatase activity of the combined enzymes was elevated over their predicted additive values. Since the effect was observed with inactive *Tb*PIP39 (i.e., in the absence of magnesium) and was not recapitulated when *Tb*PIP39 was incubated with a catalytically dead C229S mutant of *Tb*PPT1, we assign the enhanced phosphatase activity of *Tb*PPT1/*Tb*PIP39 to an activation of *Tb*PPT1. While being potentially muted by the relatively high levels of citrate in the *Escherichia coli* expression system (~5 mM), we observed that the activation of recombinant *Tb*PPT1 required a 10-fold excess of its substrate, *Tb*PIP39, in vitro. In vivo, the physiological interactions between the proteins could be enhanced significantly by their relative context or the presence of associated proteins in the cell, but nonetheless *Tb*PIP39 is in considerable excess of *Tb*PPT1 in stumpy forms (Supplemental Fig. 4D). Hence, *Tb*PIP39 is predicted to promote its own dephosphorylation by activating *Tb*PPT1. Given our finding that the Y278-phosphorylated form of *Tb*PIP39 shows greater phosphatase activity than its unphosphorylated form, these observations combine to generate a feedback loop whereby *Tb*PIP39 reinforces its own dephosphorylation, and hence repression, by activating *Tb*PPT1.

Although *Tb*PPT1 was found to be a cytosolic/cytoskeletally associated protein (Szöör et al. 2006), its substrate, *Tb*PIP39, was found to be glycosomally associated. This apparent paradox can be resolved by considering the maturation of proteins as they are trafficked to peroxisome-related organelles, such as glycosomes. Such proteins are initially translated in the cytosol and then folded. The peroxisomal targeting signal is then recognized, and the protein is translocated to the peroxisome membrane where it is imported via peroxins to the lumen. This passage through the cytosol, from synthesis to import, has been measured to take from 5 to 60 min (McNew and Goodman 1994; Terlecky et al. 2001), providing ample opportunity for *Tb*PIP39 to be phosphorylated or dephosphorylated prior to glycosome targeting.

Based on our experiments, we propose a new model for the early steps in trypanosome differentiation (Fig. 6). In stumpy forms, *Tb*PIP39 would be synthesized, but held relatively inactive through its dephosphorylation by *Tb*PPT1, this being reinforced by the enhanced activity of *Tb*PPT1 generated by its substrate when in excess. When trafficked to the glycosome, dephosphorylated, inactive *Tb*PIP39 would not stimulate differentiation. When entering the tsetse, however, temperature reduction to 20°C would facilitate CCA transport into the cell via PAD expression (Dean et al. 2009). If matching our in vitro observations, this would prevent the feedback activation of *Tb*PPT1 by *Tb*PIP39, although CCA may

Figure 6. A model depicting the regulatory interactions between *Tb*PPT1 and *Tb*PIP39 when exposed to the differentiation triggers citrate or *cis*-aconitate. The CCA signal is conveyed by PAD proteins expressed on the surface of stumpy forms. This inhibits the activation of *Tb*PPT1 by *Tb*PIP39, although *Tb*PPT1 may also be inactivated indirectly. Upon the inactivation of *Tb*PPT1, phosphorylated *Tb*PIP39 predominates, this being generated by an unidentified protein kinase. *Tb*PIP39, activated by phosphorylation, is directed toward the glycosomes by its C-terminal PTS1 signal, and therein promotes a differentiation response.

also inhibit *Tb*PPT1 indirectly through other unknown mechanisms. Combined with the enhanced expression of *Tb*PIP39 at low temperature, this would increase the level of phosphorylated *Tb*PIP39, which, upon entry to the glycosome, would promote differentiation.

The proposed pathway is reminiscent of cell fate decision pathways in other eukaryotes, whereby phosphorylation–dephosphorylation events coordinate a transition from one stable state to another—a so-called bistable switch (Pomeroy et al. 2003; Ingolia and Murray 2007). In this case, the activation of *Tb*PPT1 by *Tb*PIP39 would repress differentiation by enhancing the dephosphorylation of *Tb*PIP39, whereas exposure to CCA would alleviate this repression, favor *Tb*PIP39 phosphorylation, and so stimulate differentiation. Importantly, the sequestration of phosphorylated *Tb*PIP39 in the glycosomal compartment would protect it from further *Tb*PPT1 activity, rendering its activation irreversible. Although metabolic regulation via phosphorylation represents an obvious point of downstream control (Christofk et al. 2008) and is a known regulator of differentiation events (Milne et al. 1998; Morris et al. 2002), glycosomes are predicted to comprise >200 distinct proteins (Colasante et al. 2006; Opperdoes and Szikora 2006) associated with ether lipid biosynthesis, the β oxidation of fatty acids, purine salvage, pyrimidine biosynthesis, gluconeogenesis, and isoprenoid biosynthesis, in addition to glycolysis. Several identified DxTxT phosphatases, including Dullard, a regulator of mammalian nuclear membrane biogenesis, exhibit lipid phosphatase activity (Kim et al. 2007; Reddy et al. 2008), suggesting that these enzymes may have the potential to regulate second messenger signaling pathways. Hence, any one, or several, of the trypanosome

glycosomal activities may be regulated by *TbPIP39* with consequences independent of, or indirectly linked to (Chambers et al. 2008), metabolism.

The existence of signaling pathways directed to peroxisome-like organelles, and specifically glycosomes, has been proposed previously (Albert et al. 2005; Michels and Rigden 2006). Our experiments establish that such a pathway exists, comprising a phosphatase signaling cascade that drives an early step in cell type differentiation in African trypanosomes. Moreover, the bistable regulation of this pathway by the physiological conditions encountered during stumpy form transmission suggests a new elegance to trypanosome developmental control, linked to the biology of their key metabolic organelle, the glycosome.

Materials and methods

Parasite growth and transfection

Bloodstream form and procyclic form trypanosomes were cultured in vitro in HMI-9 medium (Hirumi and Hirumi 1984) or SDM-79 medium (Brun and Schonenberger 1979), respectively.

Culturing, differentiation, pleomorphic transfection, and cold-shock assays of parasites were performed as described in Dean et al. (2009) using the *T. brucei* AnTat1.1 90:13 cell line (Engstler and Boshart 2004), transfectants being generated using an AMAXA nucleofector protocol (T-cell nucleofection buffer, program X001) and selected using 0.5 mg mL⁻¹ puromycin. Stumpy-enriched populations were obtained by DEAE cellulose purification (Lanham 1968) of parasites 6–7 d after infection into cyclophosphamide-treated mice.

For ectopic expression, *T. brucei* Lister 427 bloodstream forms were used, these being engineered previously to express the tetracycline repressor protein (Wirtz et al. 1999), enabling regulated gene expression of wild-type or substrate-trapping forms of *TbPTP1* (Szöör et al. 2006). Established, cultured procyclic forms were *T. brucei* Lister 427.

A transgenic procyclic line expressing an N-terminal GFP fusion of PEX13, a glycosomal import protein, was created by transfection of a previously characterized expression plasmid kindly provided by Paul Michels (Université Catholique de Louvain, Brussels) (Verplaetse et al. 2009).

DNA cloning

The *TbPIP39* coding region was amplified using *TbPIP39*-specific primers Primer 1 (see Table 1) and Primer 2, and was integrated into the pGEX4T1 (GE Healthcare Lifesciences) protein expression vector for recombinant protein production. Primer 3 and Primer 4 (see Table 1) were used to insert *TbPIP39* into the

pHD451 trypanosome ectopic expression vector (Biebing et al. 1997). The pGEX4T1*TbPIP39* construct was used as a template for site-directed mutagenesis in order to mutate *TbPIP39* Tyr 278 to phenylalanine (abbreviated Y278F *TbPIP39*). This was carried out using a commercial site-directed mutagenesis kit (Stratagene) using the mutagenesis primers Primer 5 and Primer 6 (see Table 1). Recoded synthetic genes (Supplemental Fig. 10) were synthesized by Geneart (<http://www.geneart.com>), re-cloned into pHD451, and transfected into monomorphic cells already containing the pALC14*TbPIP39* RNAi plasmid as a stable integrant.

Generation of *TbPIP39* RNAi cell line

The *TbPIP39* reading frame was amplified from genomic DNA by PCR using Primer 7 and Primer 8 (Table 1), and was integrated into the HindIII–XbaI and XhoI–NdeI cloning sites of pALC14 (Pusnik et al. 2007) to generate the pALC14*TbPIP39* RNAi plasmid.

Antibody production

Polyclonal antibody was produced in rabbits against full-length recombinant *TbPIP39* by Eurogentec; an anti-peptide phospho-278Y*TbPIP39* antibody was raised in rabbits against the sequence N-ELDHWRTDE-[phospho]Y-TKC-C from the amino acid sequence at position 269–281 in *TbPIP39* (Eurogentec). The resulting antibody was affinity-purified against the phosphorylated peptide immunogen, and was counterselected against the nonphosphorylated peptide to maximize specificity.

Substrate trapping with *TbPTP1D199A*

The production and purification of the substrate-trapping mutant of *TbPTP1* (*TbPTP1D199A*) was described in Szoor et al. (2006). Purified His-*TbPTP1D199A* was mixed with His chelating Ni-NTA Agarose beads (Qiagen) for 30 min at 4°C. The beads were then collected by centrifugation and washed three times with ice-cold His purification lysis buffer (20 mM Tris, 250 mM NaCl, 1% Triton-X, 1 mM β mercaptoethanol, 5 mM Imidazole at pH 7.5–8) supplemented with complete, and EDTA-free protease inhibitor cocktail (Roche).

Approximately 5 × 10⁸ DEAE-purified *T. brucei* stumpy cells were harvested by centrifugation, and the cell pellet was frozen in liquid nitrogen. Cells were then lysed in the presence of 150 mM PTP1B inhibitor BZ3 (Calbiochem) by addition of 500 μL of His purification lysis buffer supplemented with complete, and EDTA-free protease inhibitor cocktail (Roche). The extract was lysed by two freeze/thaw cycles at –80°C, centrifuged for 20 min at 4°C in a microfuge, and then sonicated for 3 min in a water bath. Quantification of cellular protein was performed by the Bradford method following the manufacturer's instructions.

Table 1. Oligonucleotides used in the study

Oligonucleotide name	Sequence
Primer 1 (BamHI Fwd)	5'-TATGGATCCATGGTGAGGACGACACGCTTTTC-3'
Primer 2 (XhoI Rev)	5'-ATACTCGAGCTAAAGTCTTGAAGGAGTGTGTC-3'
Primer 3 (HindIII Fwd)	5'-TATAAGCTTATGGTGAGGACACGCTTTTC-3'
Primer 4 (BamHI Rev)	5'-ATAGGATCCCTAAAGTCTTGAAGGAGTGTGTC-3'
Primer 5 (Y278F Fwd)	5'-CCATTGGCGTACGGATGAGTTCACAAAGTGTGACGACTTTTCG-3'
Primer 6 (Y278F Rev)	5'-CGAAAGTCGTCACACTTTGTGAACATCCGTACGCCAATGG-3'
Primer 7 (HindIIIBamHIFwd)	5'-ATAAAGCTTGGATCCGTGAGGACGACACGCTTTTCACG-3'
Primer 8 (XhoINdeI Rev)	5'-TGCCATATGCTCGAGGGGAGTTGTAACACCTGCACCTCC-3'

Approximately 0.5 mg of fresh cell extract was incubated for 1.5 h on ice with 20–30 μ L of Ni-NTA beads coated with His-tagged protein; nonspecific interactions were removed by washing the beads three times with 1 mL of 20 mM Tris, 250 mM NaCl, and 20 mM imidazole (pH: 8.0), and the bound proteins were eluted by addition of SDS-PAGE sample buffer.

Mass spectrometry

Eluate from substrate-trapping columns was separated by SDS-PAGE, and Coomassie Blue-stained bands were excised and washed in 100 mM ammonium bicarbonate with shaking for 1 h at room temperature, followed by a second wash in 50% acetonitrile/100 mM ammonium bicarbonate. Proteins were reduced with 3 mM DTT in 100 mM ammonium bicarbonate for 30 min at 60°C, followed by alkylation with 10 mM iodoacetamide for 30 min in the dark at room temperature. The gel pieces were washed with 50% acetonitrile/100 mM ammonium bicarbonate, shaking for 1 h at room temperature, and then were dehydrated by incubation with 0.1 mL of acetonitrile for 10 min at room temperature. All liquid was removed and gel pieces were dried to completion under vacuum, then rehydrated with a sufficient volume of trypsin (Promega sequencing grade, 2 mg/mL in 25 mM ammonium bicarbonate) to cover the gel pieces. Digestion was performed overnight at 37°C, the gel pieces washed for 10 min with 0.02 mL of 1% formic acid, and then 0.02 mL acetonitrile was added. After 10 min of incubation, all liquid was transferred to a fresh tube, and the tryptic peptides were dried to completion.

Tryptic peptides were solubilized in 0.5% formic acid and 2% acetonitrile, and were fractionated on a nanoflow HPLC system (Famos/Switchos/Ultimate, LC Packings) before being analyzed by electrospray ionization (ESI) mass spectrometry on a Q-STAR Pulsar i hybrid MS/MS System. Peptide separation was performed on a Pepmap C18 reversed-phase column (LC Packings) using a 5%–85% v/v acetonitrile gradient (in 0.5% v/v formic acid) run over 45 min. The flow rate was maintained at 0.2 μ L per minute. Mass spectrometric analysis was performed using a 3-sec survey MS scan, followed by up to four MS/MS analyses of the most abundant peptides (3 sec per peak) in Information-Dependent Acquisition (IDA) mode, choosing 2+ to 4+ ions above threshold of 30 counts, with dynamic exclusion for 120 sec.

Mass spectrometry data was analyzed using Applied Biosystems Analyst QS (version 1.1) software and the automated Matrix Science Mascot Daemon server (version 2.1.06). Protein identifications were assigned using the Mascot search engine, with carbamidomethylation of cysteines and variable methionine oxidation being allowed. An MS tolerance of 1.2 Da for MS and 0.4 Da for MS/MS analysis was used. Searches were performed against the *T. brucei* genome database (version 3) obtained from the Wellcome Trust Sanger Institute and maintained on a local Mascot server.

Digitonin permeabilization assay

Approximately 5×10^8 procyclic forms were collected to perform digitonin permeabilization. The cell suspension was diluted to ~1 mg of total protein per milliliter, and increasing amounts of digitonin (0.01–5 mg/mg total protein) were used in digitonin assays according to Ferella et al. (2008).

Immunoprecipitation

Transgenic bloodstream form cell lines in which either wild-type *TbPTP1* or *TbPTP1-D199A* proteins were expressed ectopically with a C-terminal Ty1 epitope tag sequence (Szöör et al. 2006)

were treated with 6 mM *cis*-aconitate for 24 h. Immunoprecipitation was carried out using 1×10^8 to 5×10^8 cells as described in Paterou et al. (2006).

Western and Northern blotting

Western blotting and Northern blotting was performed as described in Tasker et al. (2000). For Western blotting, primary antibodies were diluted 1:1000 and secondary antibodies were diluted 1:5000. Proteins were detected using the LI-COR Odyssey system for quantification against a tubulin or loading control as described in Dean et al. (2009). For Northern blots, a digoxigenin-labeled *TbPIP39*-specific riboprobe (Roche) was used, hybridization being detected using CDP-star as a reaction substrate.

Phosphatase and kinase activity assays

Phosphatase activity was measured by monitoring the *TbPIP39*-catalyzed and *TbPTP1*-catalyzed (0.01–1 μ g) hydrolysis of pNPP to *p*-nitrophenol (Szöör et al. 2006). Phosphorylation of recombinant *TbPIP39* by FGR kinase was performed according to the manufacturer's instructions (Calbiochem). The reaction, containing purified *TbPIP39* (5 μ g), was initiated with the addition of FGR kinase, and samples were taken at time points after incubation (0, 30, 60, 90, 120, 240 min) at 30°C for Western blots. After the 240-min time point, the remainder of the phosphorylation mixture was loaded on a GSTrap HP column (GE Healthcare Life Sciences) to remove the GST-tagged FGR kinase. After collection of the flow-through from the column containing the phosphorylated *TbPIP39*, the sample was concentrated on Viva-spin 2 columns with a 10-kDa-molecular-weight cutoff (Sartorius AG) before use in the *in vitro TbPTP1* phosphatase assay.

In vitro TbPTP1 phosphatase assay

To monitor phosphatase activity of phosphorylated *TbPIP39*, the concentrated phosphorylated *TbPIP39* was treated with either 1 μ g of active wild-type *TbPTP1* or the same amount of inactive C229S *TbPTP1* mutant in a 100- μ L phosphatase assay (50 mM Tris, 50 mM Bis Tris, 100 mM Na acetate, 1mM DTT at pH 5.5). The phosphatase reaction was started with the addition of *TbPTP1*, and, after 30 min of incubation at 37°C, 20- μ L samples were removed for Western blot.

Flow cytometry and immunofluorescence

Differentiating cells (2×10^6 to 5×10^6) were harvested and fixed in 2% formaldehyde/0.05% glutaraldehyde for a minimum of 1 h at 4°C. Antibody staining was executed according to Dean et al. (2009). Flow cytometry analysis was performed using the BD LSRII Flow cytometer (Becton Dickinson), and flow cytometry data was analyzed using FlowJO 8.8.6 software (Tree Star, Inc.) with unstained cells; cells stained with only the secondary antibody provided negative controls. For immunofluorescence, air-dried smears of parasites were prepared and fixed in methanol for at least 30 min at –20°C. Cells were rehydrated in PBS for 30 min before labeling, as described in Dean et al. (2009).

Image acquisition equipment and settings

Phase-contrast and immunofluorescence microscopy images (Supplemental Fig. 7A) were captured on a Zeiss Axioskop2 (Carl Zeiss Microimaging) with a Prior Lumen 200 light source using a QImaging Retiga 2000RCCD camera; objectives were either Plan Neofluar $\times 63$ (1.25 NA) or Plan Neofluar $\times 100$ (1.30 NA).

Images were captured via QImage (QImaging). Confocal imaging (Fig. 3D) used a Leica SP5 confocal laser scanning microscope, using $\times 63$ oil immersion objective (NA = 1.4), with 4.2 zoom. The green channel was imaged using a 488-nm argon laser, and the red channel was imaged using a 543-nm helium/neon laser. The final image was acquired using Volocity Software (Improvision Ltd.) version 4.4.

Acknowledgments

We thank Achim Schnauffer for comments on the manuscript and for suggesting the use of recoded synthetic genes, Paul Michels for *TbPEx13-GFP* construct, and Michael Boshart and Markus Engstler for the gift of the *T. brucei* AnTat1.1 90:13 line. We also thank Martin Waterfall for assistance with FACS analysis. This work was supported by grants from the Wellcome Trust, the BBSRC (for the provision of confocal facilities), and by a Strategic Award from the Wellcome Trust for the Centre for Immunity, Infection, and Evolution.

References

- Albert MA, Haanstra JR, Hannaert V, Van Roy J, Opperdoes FR, Bakker BM, Michels PA. 2005. Experimental and in silico analyses of glycolytic flux control in bloodstream form *Trypanosoma brucei*. *J Biol Chem* **280**: 28306–28315.
- Bakker BM, Mensonides FI, Teusink B, van Hoek P, Michels PA, Westerhoff HV. 2000. Compartmentation protects trypanosomes from the dangerous design of glycolysis. *Proc Natl Acad Sci* **97**: 2087–2092.
- Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, Krishna S. 2003. The trypanosomiasis. *Lancet* **362**: 1469–1480.
- Bastin P, Bagherzadeh Z, Matthews KR, Gull K. 1996. A novel epitope tag system to study protein targeting and organelle biogenesis in *Trypanosoma brucei*. *Mol Biochem Parasitol* **77**: 235–239.
- Biebinger S, Wirtz LE, Lorenz P, Clayton C. 1997. Vectors for inducible expression of toxic gene products in bloodstream and procyclic *Trypanosoma brucei*. *Mol Biochem Parasitol* **85**: 99–112.
- Blanchetot C, Chagnon M, Dubé N, Hallé M, Tremblay ML. 2005. Substrate-trapping techniques in the identification of cellular PTP targets. *Methods* **35**: 44–53.
- Brenchley R, Tariq H, McElhinney H, Szoor B, Huxley-Jones J, Stevens R, Matthews K, Taberner L. 2007. The TriTryp phosphatome: Analysis of the protein phosphatase catalytic domains. *BMC Genomics* **8**: 434. doi: 10.1186/1471-2164-8-434.
- Broadhead R, Dawe HR, Farr H, Griffiths S, Hart SR, Portman N, Shaw MK, Ginger ML, Gaskell SJ, McKean PG, et al. 2006. Flagellar motility is required for the viability of the bloodstream trypanosome. *Nature* **440**: 224–227.
- Brun R, Schonenberger. 1979. Cultivation and *in vitro* cloning or procyclic culture forms of *Trypanosoma brucei* in a semi-defined medium. Short communication. *Acta Trop* **36**: 289–292.
- Chambers JW, Kearns MT, Morris MT, Morris JC. 2008. Assembly of heterohexameric trypanosome hexokinases reveals that hexokinase 2 is a regulable enzyme. *J Biol Chem* **283**: 14963–14970.
- Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. 2008. Pyruvate kinase M2 is a phosphotyrosine-binding protein. *Nature* **452**: 181–186.
- Colasante C, Ellis M, Ruppert T, Voncken F. 2006. Comparative proteomics of glycosomes from bloodstream form and procyclic culture form *Trypanosoma brucei brucei*. *Proteomics* **6**: 3275–3293.
- Collet JF, Stroobant V, Pirard M, Delpierre G, Van Schaftingen E. 1998. A new class of phosphotransferases phosphorylated on an aspartate residue in an amino-terminal DXDX (T/V) motif. *J Biol Chem* **273**: 14107–14112.
- Czichos J, Nonnengaesser C, Overath P. 1986. *Trypanosoma brucei*: Cis-aconitate and temperature reduction as triggers of synchronous transformation of bloodstream to procyclic trypomastigotes *in vitro*. *Exp Parasitol* **62**: 283–291.
- Dean SD, Marchetti R, Kirk K, Matthews K. 2009. A surface transporter family conveys the trypanosome differentiation signal. *Nature* **459**: 213–217.
- Engstler M, Boshart M. 2004. Cold shock and regulation of surface protein trafficking convey sensitization to inducers of stage differentiation in *Trypanosoma brucei*. *Genes Dev* **18**: 2798–2811.
- Fenn K, Matthews KR. 2007. The cell biology of *Trypanosoma brucei* differentiation. *Curr Opin Microbiol* **10**: 539–546.
- Ferella M, Li ZH, Andersson B, Docampo R. 2008. Farnesyl diphosphate synthase localizes to the cytoplasm of *Trypanosoma cruzi* and *T. brucei*. *Exp Parasitol* **119**: 308–312.
- Hannaert V, Saavedra E, Duffieux F, Szikora JP, Rigden DJ, Michels PA, Opperdoes FR. 2003. Plant-like traits associated with metabolism of *Trypanosoma* parasites. *Proc Natl Acad Sci* **100**: 1067–1071.
- He CY. 2007. Golgi biogenesis in simple eukaryotes. *Cell Microbiol* **9**: 566–572.
- He CY, Ho HH, Malsam J, Chalouni C, West CM, Ullu E, Toomre D, Warren G. 2004. Golgi duplication in *Trypanosoma brucei*. *J Cell Biol* **165**: 313–321.
- He CY, Pypaert M, Warren G. 2005. Golgi duplication in *Trypanosoma brucei* requires Centrin2. *Science* **310**: 1196–1198.
- Hirumi H, Hirumi K. 1984. Continuous cultivation of animal-infective bloodstream forms of an East African *Trypanosoma congolense* stock. *Ann Trop Med Parasitol* **78**: 327–330.
- Ingolia NT, Murray AW. 2007. Positive-feedback loops as a flexible biological module. *Curr Biol* **17**: 668–677.
- Kamenski T, Heilmeyer S, Meinhart A, Cramer P. 2004. Structure and mechanism of RNA polymerase II CTD phosphatases. *Mol Cell* **15**: 399–407.
- Kim Y, Gentry MS, Harris TE, Wiley SE, Lawrence JC Jr, Dixon JE. 2007. A conserved phosphatase cascade that regulates nuclear membrane biogenesis. *Proc Natl Acad Sci* **104**: 6596–6601.
- Lanham SM. 1968. Separation of trypanosomes from the blood of infected rats and mice by anion-exchangers. *Nature* **218**: 1273–1274.
- Matthews KR. 2005. The developmental cell biology of *Trypanosoma brucei*. *J Cell Sci* **118**: 283–290.
- McNew JA, Goodman JM. 1994. An oligomeric protein is imported into peroxisomes *in vivo*. *J Cell Biol* **127**: 1245–1257.
- Michels PA, Rigden DJ. 2006. Evolutionary analysis of fructose 2,6-bisphosphate metabolism. *IUBMB Life* **58**: 133–141.
- Michels PA, Bringaud F, Herman M, Hannaert V. 2006. Metabolic functions of glycosomes in *Trypanosomatids*. *Biochim Biophys Acta* **1763**: 1463–1477.
- Milne KG, Prescott AR, Ferguson MA. 1998. Transformation of monomorphic *Trypanosoma brucei* bloodstream form trypomastigotes into procyclic forms at 37 degrees C by removing glucose from the culture medium. *Mol Biochem Parasitol* **94**: 99–112.
- Morris JC, Wang Z, Drew ME, Englund PT. 2002. Glycolysis modulates trypanosome glycoprotein expression as revealed by an RNAi library. *EMBO J* **21**: 4429–4438.

- Ndubuisil MI, Kwok BH, Vervoort J, Koh BD, Elofsson M, Crews CM. 2002. Characterization of a novel mammalian phosphatase having sequence similarity to *Schizosaccharomyces pombe* PHO2 and *Saccharomyces cerevisiae* PHO13. *Biochemistry* **41**: 7841–7848.
- Opperdoes FR. 1987. Compartmentation of carbohydrate metabolism in trypanosomes. *Annu Rev Microbiol* **41**: 127–151.
- Opperdoes FR, Szikora JP. 2006. In silico prediction of the glycosomal enzymes of *Leishmania major* and trypanosomes. *Mol Biochem Parasitol* **147**: 193–206.
- Parsons M, Worthey EA, Ward PN, Mottram JC. 2005. Comparative analysis of the kinomes of three pathogenic *Trypanosomatids*: *Leishmania major*, *Trypanosoma brucei* and *Trypanosoma cruzi*. *BMC Genomics* **6**: 127. doi: 10.1186/1471-2164-6-127.
- Paterou A, Walrad P, Craddy P, Fenn K, Matthews K. 2006. Identification and stage-specific association with the translational apparatus of TbZFP3, a ccch protein that promotes trypanosome life cycle development. *J Biol Chem* **281**: 39002–39013.
- Pomerening JR, Sontag ED, Ferrell JE Jr. 2003. Building a cell cycle oscillator: Hysteresis and bistability in the activation of Cdc2. *Nat Cell Biol* **5**: 346–351.
- Pusnik M, Small I, Read LK, Fabbro T, Schneider A. 2007. Pentatricopeptide repeat proteins in *Trypanosoma brucei* function in mitochondrial ribosomes. *Mol Cell Biol* **27**: 6876–6888.
- Reddy VS, Singh AK, Rajasekharan R. 2008. The *Saccharomyces cerevisiae* PHM8 gene encodes a soluble magnesium-dependent lysophosphatidic acid phosphatase. *J Biol Chem* **283**: 8846–8854.
- Selengut JD, Levine RL. 2000. MDP-1: A novel eukaryotic magnesium-dependent phosphatase. *Biochemistry* **39**: 8315–8324.
- Siniosoglou S, Hurt EC, Pelham HR. 2000. Psr1p/Psr2p, two plasma membrane phosphatases with an essential DXDX (T/V) motif required for sodium stress response in yeast. *J Biol Chem* **275**: 19352–19360.
- Sogin ML, Elwood HJ, Gunderson JH. 1986. Evolutionary diversity of eukaryotic small-subunit rRNA genes. *Proc Natl Acad Sci* **83**: 1383–1387.
- Stuart KD, Schnauffer A, Ernst NL, Panigrahi AK. 2005. Complex management: RNA editing in trypanosomes. *Trends Biochem Sci* **30**: 97–105.
- Szöör B, Wilson J, McElhinney H, Taberner L, Matthews KR. 2006. Protein tyrosine phosphatase TbPTP1: A molecular switch controlling life cycle differentiation in trypanosomes. *J Cell Biol* **175**: 293–303.
- Tasker M, Wilson J, Sarkar M, Hendriks E, Matthews K. 2000. A novel selection regime for differentiation defects demonstrates an essential role for the stumpy form in the life cycle of the African trypanosome. *Mol Biol Cell* **11**: 1905–1917.
- Terlecky SR, Legakis JE, Hueni SE, Subramani S. 2001. Quantitative analysis of peroxisomal protein import *in vitro*. *Exp Cell Res* **263**: 98–106.
- Teusink B, Walsh MC, van Dam K, Westerhoff HV. 1998. The danger of metabolic pathways with turbo design. *Trends Biochem Sci* **23**: 162–169.
- Verplaetse E, Rigden DJ, Michels PA. 2009. Identification, characterization and essentiality of the unusual peroxin 13 from *Trypanosoma brucei*. *Biochim Biophys Acta* **1793**: 516–527.
- Wirtz E, Leal S, Ochatt C, Cross GA. 1999. A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in *Trypanosoma brucei*. *Mol Biochem Parasitol* **99**: 89–101.
- Xue Y, Zhou F, Zhu M, Ahmed K, Chen G, Yao X. 2005. GPS: A comprehensive www server for phosphorylation sites prediction. *Nucleic Acids Res* **33**: W184–W187. doi: 10.1093/nar/gki393.

A novel phosphatase cascade regulates differentiation in *Trypanosoma brucei* via a glycosomal signaling pathway

Balázs Szöör, Irene Ruberto, Richard Burchmore, et al.

Genes Dev. 2010, **24**:

Access the most recent version at doi:[10.1101/gad.570310](https://doi.org/10.1101/gad.570310)

Supplemental Material <http://genesdev.cshlp.org/content/suppl/2010/06/09/24.12.1306.DC1>

Related Content **Bistable Trypanosome Switch**
Annalisa M. VanHook
Sci. Signal. June , 2010 3: ec186

References This article cites 52 articles, 19 of which can be accessed free at:
<http://genesdev.cshlp.org/content/24/12/1306.full.html#ref-list-1>
Articles cited in:
<http://genesdev.cshlp.org/content/24/12/1306.full.html#related-urls>

License Freely available online through the Genes & Development Open Access option.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

Focused on your science.

USC
SCIENTIFIC
SIDE BY SCIENCE